OPKO Health, Inc. (OPK) stock
OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/305% above fair value
$1.62+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.21BP/E –Yield –
OPKO Health r&d expenses
Research and development expenses are spending on new products and technology.
OPKO Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $125.22M, up 4.0% year over year. For fiscal 2025 it was $124.03M, up 17.9% from the year before. Over ten years it grew 2.2% a year on average. The highest annual figure on record is $126.44M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.03M | +17.9% |
| FY2024 | Dec 31, 2024 | $105.21M | +17.4% |
| FY2023 | Dec 31, 2023 | $89.59M | +21.3% |
| FY2022 | Dec 31, 2022 | $73.89M | -3.9% |
| FY2021 | Dec 31, 2021 | $76.85M | +2.0% |
| FY2020 | Dec 31, 2020 | $75.32M | -36.1% |
| FY2019 | Dec 31, 2019 | $117.87M | -6.1% |
| FY2018 | Dec 31, 2018 | $125.59M | -0.7% |
| FY2017 | Dec 31, 2017 | $126.44M | +11.0% |
| FY2016 | Dec 31, 2016 | $113.87M | +14.5% |
| FY2015 | Dec 31, 2015 | $99.49M | +19.0% |
| FY2014 | Dec 31, 2014 | $83.57M | +55.0% |
| FY2013 | Dec 31, 2013 | $53.90M | +176.1% |
| FY2012 | Dec 31, 2012 | $19.52M | +72.0% |
| FY2011 | Dec 31, 2011 | $11.35M | +90.8% |
| FY2010 | Dec 31, 2010 | $5.95M | -45.1% |
| FY2009 | Dec 31, 2009 | $10.84M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $33.17M | +9.3% |
| Q1 FY2026 | Mar 31, 2026 | $29.20M | -5.3% |
| Q4 FY2025 | Dec 31, 2025 | $32.77M | +7.7% |
| Q3 FY2025 | Sep 30, 2025 | $30.08M | +4.5% |
| Q2 FY2025 | Jun 30, 2025 | $30.34M | +26.0% |
| Q1 FY2025 | Mar 31, 2025 | $30.84M | +40.6% |
| Q4 FY2024 | Dec 31, 2024 | $30.43M | +56.9% |
| Q3 FY2024 | Sep 30, 2024 | $28.77M | +48.0% |
| Q2 FY2024 | Jun 30, 2024 | $24.08M | +32.6% |
| Q1 FY2024 | Mar 31, 2024 | $21.94M | -32.7% |
| Q4 FY2023 | Dec 31, 2023 | $19.39M | -0.7% |
| Q3 FY2023 | Sep 30, 2023 | $19.44M | +3.4% |
| Q2 FY2023 | Jun 30, 2023 | $18.16M | +5.2% |
| Q1 FY2023 | Mar 31, 2023 | $32.61M | +78.1% |
| Q4 FY2022 | Dec 31, 2022 | $19.53M | -7.0% |
| Q3 FY2022 | Sep 30, 2022 | $18.79M | +2.7% |
| Q2 FY2022 | Jun 30, 2022 | $17.25M | -5.3% |
| Q1 FY2022 | Mar 31, 2022 | $18.31M | -5.2% |
| Q4 FY2021 | Dec 31, 2021 | $21.01M | +20.4% |
| Q3 FY2021 | Sep 30, 2021 | $18.31M | -1.0% |
| Q2 FY2021 | Jun 30, 2021 | $18.22M | +3.5% |
| Q1 FY2021 | Mar 31, 2021 | $19.32M | -11.2% |
| Q4 FY2020 | Dec 31, 2020 | $17.45M | -24.2% |
| Q3 FY2020 | Sep 30, 2020 | $18.49M | -38.4% |
| Q2 FY2020 | Jun 30, 2020 | $17.61M | -37.8% |
| Q1 FY2020 | Mar 31, 2020 | $21.76M | -40.4% |
| Q4 FY2019 | Dec 31, 2019 | $23.04M | -30.9% |
| Q3 FY2019 | Sep 30, 2019 | $30.02M | -0.5% |
| Q2 FY2019 | Jun 30, 2019 | $28.29M | -3.2% |
| Q1 FY2019 | Mar 31, 2019 | $36.53M | +11.1% |
| Q4 FY2018 | Dec 31, 2018 | $33.33M | -2.7% |
| Q3 FY2018 | Sep 30, 2018 | $30.16M | -7.2% |
| Q2 FY2018 | Jun 30, 2018 | $29.21M | -11.8% |
| Q1 FY2018 | Mar 31, 2018 | $32.89M | +23.8% |
| Q4 FY2017 | Dec 31, 2017 | $34.24M | +13.1% |
| Q3 FY2017 | Sep 30, 2017 | $32.51M | +33.1% |
| Q2 FY2017 | Jun 30, 2017 | $33.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $26.56M | – |
| Q4 FY2016 | Dec 31, 2016 | $30.28M | – |
| Q3 FY2016 | Sep 30, 2016 | $24.42M | – |
See a number that looks wrong?